How Adaptive Trial Designs Can Increase Efficiency in Psychiatric Drug Development: A Case Study

| July 31, 2011 | 0 Comments

 
by Joan Shen, MD; Sheldon Preskorn, MD; Vladimir Dragalin, PhD; Mary Slomkowski, PharmD; S. Krishna Padmanabhan, PhD; Parvin Fardipour, PhD; Amarnath Sharma, PhD; and Michael Krams, MD, PhD
Dr. Shen is Senior Director, Pfizer Inc., Collegeville, Pennsylvania; Dr. Preskorn is Professor in
the Department of Psychiatry and Behavioral Sciences, University of Kansas School of Medicine, Wichita, Kansas; Dr. Dragalin is Senior Vice President, Aptiv Solutions, Raleigh, North Carolina; Dr. Slomkowski is Director, Pfizer Inc., Collegeville, Pennsylvania; Dr. Padmanabhan is Senior Principal Statistician, Pfizer Inc., Collegeville, Pennsylvania; Dr. Fardipour is Senior Director, Pfizer Inc., Collegeville, Pennsylvania; Dr. Sharma is Vice President, Pfizer Inc., Collegeville, Pennsylvania; and Dr. Krams is Vice President, Janssen Pharmaceuticals, Titusville, New Jersey.

Innov Clin Neurosci. 2011;8(7):26–34

The content you are trying to view is restricted to registered members only.
Membership to Innovations in Clinical Neuroscience is free, so please consider becoming a member today.
Thank you
ICNS Online Editor
Please Login or Register for access.

Tags: , , , ,

Category: Case Study, Drug Development, Psychiatry, Psychopharmacology, Schizophrenia, Suicidality, Trial Methodology

Leave a Reply